François Laliberté/LinkedIn
Aug 6, 2025, 12:52
RPTH Journal: Rivaroxaban vs Warfarin in PE with RV Dysfunction
RPTH Journal shared a new study on LinkedIn:
”Do clinical outcomes differ between patients treated with rivaroxaban vs warfarin for PE/RVD?
Rivaroxaban was more effective than warfarin without a significant increase in safety.”
Read the full article here.
Article: Effectiveness and safety of rivaroxaban vs warfarin in patients with pulmonary embolism and right ventricular dysfunction: a retrospective cohort study
Authors: François Laliberté, Behnood Bikdeli, Veronica Ashton, Guillaume Germain, Julien Boudreau, Manasvi Sundar, Sean D. MacKnight, Brahim Bookhart, Dereck Wentworth, Shawn Murphy, Yichuan G. Hsieh, Gregory Piazza
Find the latest scientific advances featured in Hemostasis Today.
Behnood Bikdeli
Brahim Bookhart
Dereck Wentworth
François Laliberté
Gregory Piazza
Guillaume Germain
Health
Hematology
Hemostasis Today
Julien Boudreau
Manasvi Sundar
Medicine
PE
Pulmonary embolism
right ventricular dysfunction
Rivaroxaban
Rivaroxaban vs Warfarin
RPTH Journal
RVD
Sean D. MacKnight
Shawn Murphy
Veronica Ashton
Warfarin
Yichuan G. Hsieh
-
Jan 7, 2026, 13:57Joshua Muia: Delighted to Welcome X. Long Zheng for a Versiti Seminar on TTP
-
Jan 7, 2026, 13:40Marilena Vrana Invites You to IPPC2026
-
Jan 7, 2026, 13:32Carlos Villa Joins Versiti Blood Research Institute
-
Jan 7, 2026, 13:21Bartosz Hudzik: New Evidence on “Aspirin Failure” After Ischemic Stroke
-
Jan 7, 2026, 08:50Fahad Khaliq on When is Ticagrelor Preferred Over Other Antiplatelets
-
Jan 7, 2026, 06:41Zain Khalpey on AI Driven Risk Prediction for Optimization of Anticoagulation in LVAD
-
Jan 7, 2026, 05:47Michael Makris: The Wakley Prize Essay Published in Today’s Lancet is an Excellent Read
-
Jan 7, 2026, 05:36Pierre F Sabouret Shares A Study on the Risk of Cardiovascular Death in SIDs
-
Jan 7, 2026, 05:15Glaivy Batsuli Reflects on ASH25